Company Announcements - 2009
-
Market Update24 December 2009
Further to the announcement to the market on 12 October 2009, Analytica Limited wishes to advise that its Pre-Market Notification (510(k)) application for the AutoStart® Burette is still under consideration by the FDA Office for Device Evaluation. Analytica understands that that the FDA workload is currently unusually high due to the agency?s recent change in premises.
Analytica is not aware of any impediment to the AutoStart® Burette receiving the required approvals from the FDA to be marketed in the United States and will advise the market of further developments as they occur.
The Company also remains on target to complete a formal distribution & licensing agreement with Medical Australia Limited (MLA) in the New Year. The Agreement will provide MLA with an exclusive right for the distribution of the AutoStart® Burette in Australia, New Zealand and the UK, with a springboard into Asia, Europe & the middle east.
-
Correction - Location of Share Register23 December 2009The announcement made by the Company on 21 December concerning the location of its share registry, Link Market Services, contained a typographical error. Link Market Services has relocated to Level 15, 324 Queen Street, Brisbane 4000. The previous announcement incorrectly stated Level 19. All telephone and fax numbers remain unchanged.
-
Location of Share Register21 December 2009Analytica Limited (ASX: ALT) advises in accordance with Listing Rule 3.15.1, that the Company?s share registry, Link Market Services, has relocated to Level 19, 324 Queen Street, Brisbane 4000. All telephone and fax numbers remain unchanged.
-
Appendix 3B4 December 2009New issue announcement, application for quotation of additional securities and agreement.
-
Appendix 3Y4 December 2009Change of Director's Interest Notice.
-
Annual General Meeting27 November 2009
-
Medical Australia and Analytica Sign Licensing and Distribution Heads of Agreement.26 November 2009
? Multifaceted agreement including the manufacture, regulatory sponsorship and marketing of the Analytica AutoStart® Burette device and AutoFlush feature.
? Exclusive distribution opportunity encompassing Australia, New Zealand and UK, with springboard into Asia, Middle East and EU.
? Long-term strategic alliance to form product development, commercialisation and distribution partnership.
-
Trading Halt25 November 2009Pursuant to listing Rule 17.1, Analytica Limited requests an immediate trading halt of the company's securities ("ASX: ALT") pending the release of a material announcement concerning the distribution of the company's AutoStart® Burette product. The company expects to make this announcement before the opening of trade on Friday morning (Nov 27).
-
ASX Price Query Response5 November 2009Response to query by the ASX regarding recent price changes.
-
First Commercial Sale of AutoStart® Burette30 October 2009Analytica is pleased to announce that it has received its first commercial order for the AutoStart® Burette following extensive trials with a State Government Hospital. This order marks a major milestone in the product lifecycle and moves Analytica's focus from development to production.
-
Company Update - FDA 510(k) Application Acceptance12 October 2009Analytica is pleased to announce that the US Food and Drug Administration has received and accepted a Premarket Notification (510(k)) application for the AutoStart® Burette. The 510(k) is a submission made to the FDA demonstrating that the AutoStart Burette is at least as safe and effective as existing legally marketed burette devices. Before supplying the AutoStart Burette to the US, Analytica must receive a letter from FDA which finds the device to be substantially equivalent and clears the device to be marketed. 510(k) clearances typically take several months.
-
Appendix 4C - Quarterly Cash Flow1 October 2009Analytica presents its Appendix 4C for the quarter ended 30 September 2009
-
Notice of Annual General Meeting25 September 2009The Annual General Meeting of Analytica Ltd will be held at 10:00am (Brisbane time) Friday 27 November 2009 in the Heritage Function Room, The Glen Hotel, Corner Logan Road and Gaskell St, Eight Mile Plains.
-
Annual Report for the year ended 30 June 2009.15 September 2009
-
Appendix 4E.27 August 2009Preliminary Final Report.
-
Appendix 3Y27 August 2009Change of Director?s Interest Notice (Dr M Monsour).
-
Appendix 3Y27 August 2009Change of Director?s Interest Notice (Mr D Gooch).
-
Completion of Share Purchase Plan & Appendix 3B.25 August 2009Analytica Limited is pleased to announce that is has raised $879,245 from subscriptions under its recent Share Purchase Plan (SPP). All eligible applicants will receive their full entitlement. Allotment of SPP shares will take place effective 25 August 2009 with the dispatch of Allotment Notices expected to occur by 28 August. The funds raised under the SPP have exceeded the Boards expectations and will be used in bringing the AutoStart® Burette to market as well as meeting the Company?s working capital requirements over the coming months. An Appendix 3B will follow this announcement.
-
Location of Share Register.24 August 2009Analytica Limited advises in accordance with Listing Rule 3.15.1, that from Monday 24 August 2009, the Company?s share registry, Link Market Services, will be located in the ANZ Building, Level 19, 324 Queen Street, Brisbane 4000. All telephone and fax numbers remain unchanged.
-
AutoStart Burette Update.13 August 2009Analytica is pleased to announce its AutoStart® Burette has now formally completed its first in-hospital trial. This trial, conducted in a Queensland hospital, successfully demonstrated the effectiveness and usability of the AutoStart® Burette in a clinical environment.
-
Passing of Mr Jim Heckathorn & Appendix 3Z22 July 2009It is with much sadness that the Board of Analytica Limited announces the passing of Director Mr. Jim Heckathorn. Mr. Heckathorn passed away overnight after a brief illness. An Appendix 3Z is attached to this announcement.
-
Share Purchase Plan20 July 2009Analytica Limited is pleased to announce a Share Purchase Plan (SPP) to address its future funding needs. Under the SPP, we would like to invite eligible shareholders to participate by purchasing up to $15,000 of ALT ordinary shares without incurring brokerage or transaction costs.
-
Appendix 4C - Quarterly Cash Flow and Unaudited Full-year Result.31 July 2009Analytica Ltd presents its Appendix 4C for the quarter ended 30 June 2009.
-
Company Update.13 July 2009Analytica Limited is pleased to provide the attached update to the market on the Company?s activities.
-
Appendix 3Y - Change of Director?s Interest Notice.18 June 2009Attached to this announcement is an Appendix 3Y-Change of Directors Interest Notice relating to a share sale by Analytica Non-executive director Mr Jim Heckathorn.
-
Appendix 3Y5 May 2009Change of Director?s Interest Notice.
-
Appendix 4C - Quarterly Cash Flow29 April 2009Analytica Ltd presents its Appendix 4C for the quarter ended 31 March 2009 and an update on developments in the Company.
-
Company Update9 April 2009Analytica Limited has made a strategic investment in the Australian unlisted Biotechnology company CBio Limited. Analytica has subscribed for Convertible Notes totaling $500,000 with the intention of acquiring additional notes over the coming months.
-
Appendix 3Y3 April 2009Change of Director?s Interest Notice.
-
AutoStart Burette Update24 February 2009Analytica wishes to update the market on the evaluations being conducted on the Company?s AutoStart® Burette by potential licensee companies.
-
Appendix 4D - Half Year Report24 February 2009Half Year Report for the 6 months ended December 2008 (current period) and the previous corresponding period 6 months ended 31 December 2007
-
Preliminary Half-Yearly Result18 February 2009Analytica Limited wishes to advise the market that the loss for the half-year ended 31 December 2008 will be substantially higher than the loss recorded for corresponding period in 2007, and will also be higher than the loss recorded for the year ended 30 June 2008.
-
Appendix 3Y30 January 2009Change of Director?s Interest Notice.
-
Appendix 4C - Quarterly Cash Flow29 January 2009Analytica presents its Appendix 4C for the quarter ended 31 December 2008 and an update on developments in the Company.
-
Appendix 3B16 January 2009New issue announcement, application for quotation of additional securities and agreement.
-
Appendix 3B - New issue announcement, application for quotation of additional securities and agreement06 January 2009Analytica Ltd has today issued a further 37,547,512 shares upon the exercise of unlisted options which expired on 31 December 2008. The Company has received Notices exercising further options (expiring 31 December 2008) for which funds have not yet cleared. It is expected that these remaining shares will be allotted during the week ending 16 January.
-
Appendix 3Y - Change of Director?s Interest Notice (x3)06 January 2009Please find attached to this announcement Appendix 3Y?s in relation to the exercise of unlisted options by Directors Dr Michael Monsour and Mr Jim Heckathorn. Also attached is a corrected Appendix 3Y with respect to the options exercised by Mr Ross Mangelsdorf on 23 December. The Appendix 3Y lodged on 24 December incorrectly stated the 'date of change' as 28 November 2008. The correct 'date of change' is 23 December 2008.